Investors
Annual General Meeting 2025
Genmab's Annual General Meeting 2025 took place on Wednesday, March 12, 2025.
Learn more
About Genmab
Leading antibody science for better futures
As a leading international biotechnology company, we believe in the transformative power of science and technology.
Genmab Publishes 2024 Annual Report
On February 12, Genmab announced its full-year financial results for 2024.
Previous
Next
ABOUT US
Antibody Science, Collaborative Mindset
We strive to improve the lives of people with cancer and other serious diseases by creating and developing innovative antibody-based products.
Antibody Science
We’re pioneering technologies that aim to transform the treatment of cancer and other serious diseases.
Our pioneering technologies create next-generation therapeutic antibodies to treat cancer and other serious diseases.
Science
Unlocking the Power of the Immune Complement System to Advance Cancer Therapies
Our Impact
World Cancer Day: Fueling the Future of Cancer Care
Genmab Hosts First Awardee of the Genmab Jan van de Winkel Scholarship Fund
Our Philanthropic Responsibility to Support Patient-Focused Organizations
Meet the team
Uniquely us.
Powered by our team of dedicated employees who are focused on improving patients’ lives.
Are you looking for a new challenge? Do you want to make a real difference in the world? We might just be the right match.